HLA
DRNA

Hamilton Lane Advisors’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Hamilton Lane Advisors’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-17,462
Closed -$447K – 97
2021
Q1 		$447K Sell
17,462
-12,443
-42% -$318K 0.15% 57
2020
Q4 		$659K Buy
29,905
+16,329
+120% +$360K 0.25% 41
2020
Q3 		$244K Buy
+13,576
New +$281K 0.12% 43

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Hamilton Lane Advisors's DRNA Position: Q2 2021 in Review

Hamilton Lane Advisors sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q2 2021, closing a stake of 17,462 shares — an estimated $447K sold.

Hamilton Lane Advisors first reported a position in DRNA in Q3 2020 and held it in 3 quarters. The position peaked at $659K in Q4 2020. 203 funds tracked by Wall St. Rank hold DRNA as of Q2 2021.

  • Hamilton Lane Advisors reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Hamilton Lane Advisors sold 17,462 Dicerna Pharmaceuticals, Inc. shares in Q2 2021, an estimated $447K.
  • Hamilton Lane Advisors first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2020 and held it in 3 quarters.
  • Hamilton Lane Advisors's Dicerna Pharmaceuticals, Inc. position peaked at $659K in Q4 2020.
  • 203 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q2 2021.

Based on Hamilton Lane Advisors's 13F filing for Q2 2021, filed 20 Jul 2021.